{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:48:53Z","timestamp":1782496133088,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009874","name":"Universit\u00e9 de Sherbrooke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.anai.2026.03.028","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:31:50Z","timestamp":1775896310000},"page":"116-123.e26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-6886","authenticated-orcid":false,"given":"Simon","family":"Couillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayia","family":"Petousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"T\u00e9tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Lemaire-Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ledanois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9anne","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermin","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lachapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.03.028_bib0001","doi-asserted-by":"crossref","unstructured":"To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):1-8.","DOI":"10.1186\/1471-2458-12-204"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaci.2011.11.006","article-title":"Severe asthma: advances in current management and future therapy","volume":"129","author":"Barnes","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.03.028_bib0003","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(20)30053-9","article-title":"Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial","volume":"8","author":"Pavord","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.anai.2026.03.028_bib0004","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.anai.2026.03.028_bib0005","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the Liberty ASTHMA QUEST study: a post hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0006","first-page":"1","article-title":"Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma","volume":"59","author":"Kraft","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0007","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.anai.2026.03.028_bib0008","first-page":"1307","article-title":"Efficacy of Tezepelumab in severe, uncontrolled asthma: pooled analysis of PATHWAY and NAVIGATOR studies","volume":"207","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with Benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2026.03.028_bib0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0011","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01785-2017","article-title":"Predictors of accelerated decline in lung function in adult-onset asthma","volume":"51","author":"Coumou","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2026.03.028_bib0013","first-page":"A3418","article-title":"FeNO as a potential prognostic and predictive marker of lung function decline in patients with uncontrolled, moderate-to-severe asthma: Liberty ASTHMA QUEST","volume":"205","author":"Pavord","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0014","article-title":"Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study","volume":"57","author":"Park","year":"2021","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2026.03.028_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058215","article-title":"Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling","volume":"12","author":"Couillard","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.anai.2026.03.028_bib0017","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/thorax-2023-220972","article-title":"Type 2 inflammation and lung function decline in chronic airway disease in the general population","volume":"79","author":"\u00c7olak","year":"2024","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0018","first-page":"101","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2026.03.028_bib0019","first-page":"1785","article-title":"Towards a predict and prevent approach in obstructive airways diseases","volume":"10","author":"Couillard","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.anai.2026.03.028_bib0020","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2026.03.028_bib0021","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaip.2025.05.012","article-title":"Treat-to-target\u201d: a call for earlier targeted intervention in asthma","volume":"13","author":"Couillard","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2026.03.028_bib0022","first-page":"345","article-title":"Normal FEV1 without reversibility in asthma trials \u2013 a placebo patient-level meta-analysis","volume":"211","author":"Couillard","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0023","first-page":"145","article-title":"Identifying super-responders: a review of the road to asthma remission","volume":"133","author":"Mailhot-Larouche","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2026.03.028_bib54","unstructured":"Couillard S, Meulmeester FL, Charland P, Lemaire-Paquette S, Howell I. Celis-Preciado C, et al. Evaluating symptom burden to characterise, predict, and prevent asthma attacks: a patient-level analysis of randomised trials and translational prospective studies. Lancet Respir Med. Accessed April 29, 2026. In press."},{"issue":"4","key":"10.1016\/j.anai.2026.03.028_bib0024","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.anai.2026.03.028_bib0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type 2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (FeNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.anai.2026.03.028_bib0026","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.anai.2026.03.028_bib0028","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.chest.2021.07.008","article-title":"How I Do it. Work-up of severe asthma","volume":"160","author":"Couillard","year":"2021","journal-title":"Chest"},{"issue":"10118","key":"10.1016\/j.anai.2026.03.028_bib0029","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2026.03.028_bib0030","first-page":"781","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2026.03.028_bib0032","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0033","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0034","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with Type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0035","first-page":"e123","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.anai.2026.03.028_bib0036","first-page":"457","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.03.028_bib0037","first-page":"1580","article-title":"Use of high-dose inhaled corticosteroids and risk of corticosteroid-related adverse events in asthma findings from the NORDSTAR cohort","volume":"13","author":"von B\u00fclow","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0038","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of dose of inhaled corticosteroids and frequency of adverse events","volume":"211","author":"Bloom","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.anai.2026.03.028_bib0039","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.jaip.2025.10.012","article-title":"Biomarker suppression in asthma: how low can you go?","volume":"13","author":"St-Pierre","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2026.03.028_bib0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/17476348.2024.2380072","article-title":"Type 2 severe asthma: pathophysiology and treatment with biologics","volume":"18","author":"Pelaia","year":"2024","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.anai.2026.03.028_bib0041","doi-asserted-by":"crossref","unstructured":"Couillard S, Pavord ID. Biological therapies for asthma. In: James S, ed. Encyclopedia of Respiratory Medicine. 2nd ed. Elsevier; 2022:411-434.","DOI":"10.1016\/B978-0-08-102723-3.00071-8"},{"key":"10.1016\/j.anai.2026.03.028_bib0042","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. Available at: https:\/\/ginasthma.org\/. Accessed April 29, 2026."},{"issue":"8","key":"10.1016\/j.anai.2026.03.028_bib0043","first-page":"655","article-title":"Clinical remission attainment, definitions and correlates among biologic-treated patients with severe asthma: a systematic review and meta-analysis","volume":"12","author":"Shackleford","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"18","key":"10.1016\/j.anai.2026.03.028_bib0052","first-page":"1723","article-title":"Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years","volume":"393","author":"Leon","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.03.028_bib0053","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S2213-2600(25)00390-X","article-title":"Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"14","author":"Jenkins","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2026.03.028_bib55","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across 8 patient groups: a multi-country study","volume":"22","author":"Janssen","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.anai.2026.03.028_bib56","series-title":"Basic Information on How to Use the EQ-5D-5L Instrument","year":"2015"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00229.x","article-title":"Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma","volume":"11","author":"Chen","year":"2008","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0044","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0045","first-page":"112","article-title":"Win ratio analysis to clarify clinical benefits: a post hoc analysis of Phase 3 BOREAS and NOTUS","volume":"169","author":"Ramakrishnan","year":"2026","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2026.03.028_bib0046","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations - Standardizing endpoints for clinical asthma trials and clinical practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2026.03.028_bib0047","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.anai.2026.03.028_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.anai.2026.03.028_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081660","article-title":"SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials","volume":"389","author":"Hr\u00f3bjartsson","year":"2025","journal-title":"BMJ"},{"issue":"7748","key":"10.1016\/j.anai.2026.03.028_bib0050","first-page":"698","article-title":"CONSORT Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.anai.2026.03.028_bib0051","article-title":"Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)","volume":"66","author":"Celis-Preciado","year":"2025","journal-title":"Eur Respir J"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062600150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112062600150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:02:44Z","timestamp":1782493364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112062600150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S108112062600150X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.03.028","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}